Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles...

Area of Science:

• Biotechnology
• Nanomedicine
• Oncology

Background:

• PIK-75 is a potent multikinase inhibitor with preclinical anti-cancer activity.
• Limited solubility of PIK-75 hinders its clinical application.
• Scavenger receptor class B type 1 (SR-B1) is overexpressed in various cancers.

Purpose of the Study:

• To develop a nanoparticle formulation for targeted delivery of PIK-75.
• To investigate the efficacy of PIK-75 loaded nanoparticles in cancer models.

Main Methods:

• Synthesis of HDL-like nanoparticles (oc-HDL NP) using organic core platforms.
• Encapsulation of PIK-75 into oc-HDL NPs.
• Evaluation of PIK-75 oc-HDL NP targeting of SR-B1 and anti-cancer activity in vitro and in vivo.

Main Results:

• PIK-75 was successfully formulated into oc-HDL NPs with similar characteristics to natural HDL.
• PIK-75 oc-HDL NPs specifically targeted SR-B1 and induced potent cell death in prostate cancer and cutaneous T-cell lymphoma models.
• PIK-75 oc-HDL NPs demonstrated significant anti-cancer activity in vitro and in vivo, reducing IC50 values.

Conclusions:

• Drug-loaded oc-HDL NPs represent a promising strategy for targeted cancer therapy.
• This novel nanoparticle system actively targets SR-B1 for effective cancer cell killing.
• Further development of PIK-75 oc-HDL NPs holds potential for clinical translation.